Glioblastoma
Conditions
Interventions
High TNF expression group:None
Low TNF expression group:None
Sponsors
The First Affiliated Hospital of the Army Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histopathologically confirmed glioblastoma (WHO grade 4), IDH-wildtype (according to the 2021 WHO Classification of Tumors of the Central Nervous System); 2. No preoperative radiotherapy, chemotherapy, or immunotherapy; underwent gross total resection followed by standard postoperative radiochemotherapy; 3. Complete clinical data (including imaging profiles and follow-up data); 4. Availability of archived samples in the biobank of our hospital, with sufficient tissue for subsequent histopathological staining and molecular marker detection.
Exclusion criteria
Exclusion criteria: 1. Patients with concurrent other malignant tumors or severe autoimmune diseases; 2. Recurrent glioma; 3. Perioperative death due to complications, resulting in a lack of valid follow-up data.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival;Progression-free survival;Ionized calcium-binding adapter molecule 1(IBA1);tumor necrosis factor a (TNFa);1-year survival rate;2-year survival rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Hematoxylin-eosin staining; | — |
Countries
China
Contacts
Public ContactShi Yu
The First Affiliated Hospital of the Army Medical University
Outcome results
None listed